Erratum to: The potential utility of tildrakizumab: an interleukin-23 inhibitor for the treatment of psoriasis (Expert Opinion on Investigational Drugs, (2017), 26, 2, (243-249), 10.1080/13543784.2017.1274734)

Health (London) 2022; 26(2):e263

## **ARTICLE IDENTIFIERS**

DOI: 10.1177/13634593221076602 PMID: unavailable PMCID: not available

## JOURNAL IDENTIFIERS

LCCN: 97652924 pISSN: 1363-4593 eISSN: 1461-7196 OCLC ID: 37261992 CONS ID: not available US National Library of Medicine ID: 9800465

This article was identified from a query of the SafetyLit database.